- Flamma has agreed to acquire Lundbeck Pharmaceuticals Italy SpA (LuPI) from H. Lundbeck A/S, with the transaction expected to close on January 1, 2027.
- The Padova site will add up to 220 m³ of manufacturing capacity and enable Flamma to operate four cGMP API manufacturing sites in Northern Italy.
Flamma, a Contract Development and Manufacturing Organization (CDMO) focused on small molecule APIs, peptides and advanced intermediates, has entered into an agreement to acquire Lundbeck Pharmaceuticals Italy SpA (LuPI) from H. Lundbeck A/S. The transaction is subject to customary closing conditions and is expected to close on January 1, 2027.
The Padova facility will contribute up to 220 m³ of manufacturing capacity, bringing Flamma’s total capacity in Italy to approximately 1,100 m³. The site includes an API manufacturing workshop recently approved by AIFA, along with capabilities in hydrogenation, micronization, high-pressure chemistry, hazardous chemistry and high-containment manufacturing.
Following completion, Flamma will operate four cGMP API manufacturing sites in close proximity in Northern Italy, in addition to manufacturing operations in China and the United States. The company said the acquisition will expand its ability to support pharmaceutical innovators from early-stage development through commercial supply.
The acquisition is part of Flamma’s strategy to build a global CDMO platform focused on complex small molecule APIs, as well as high-value amino acids and peptides. The company said the expanded manufacturing capacity will be combined with its technical expertise, regulatory capabilities and workforce to support pharmaceutical innovators worldwide.
“The acquisition of the Padova site represents a strategic investment in Flamma’s growth and in the future of our customers.”
Gian Paolo Negrisoli, Chairman of the Board of Directors and CEO of Flamma
Tine Bryan Stensbøl, interim Head of Product Development & Supply at Lundbeck, said the company believes the divestment is the right move for both LuPI and Lundbeck as Lundbeck’s future small molecule manufacturing needs can be covered by its facility in Lumsås, Denmark.
